OncLive TV

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.

Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.

Nikhil Khushalani, MD, discusses the mechanism of action vusolimogene oderparepvec in cancer care.

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

Christopher A. Fausel, PharmD, MHA, BCOP, discusses how genetic sequencing has played a growing role in cancer care.

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.

Helen Heng-Shan Moon, MD, discusses the utilization of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Howard D. Edington, MD, discusses the importance of prevention strategies in melanoma.

Mike Cusnir, MD, discusses the most effective uses of chemotherapy in colorectal cancer.

Roger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).

Maria E. Cabanillas, MD, an oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses how to deliver the optimal surgical approach to patients with medullary thyroid cancer.

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

Maria E. Cabanillas, MD, oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses current systemic treatments in medullary thyroid cancer, along with the potential for peptide receptor radionuclide therapy.

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Moshe Ornstein, MD, MA, discusses the efficacy findings from a phase 2 trial examining neoadjuvant avelumab and axitinib in renal cell carcinoma.

Dan Pollyea, MD, MS, discusses the current role of maintenance therapy in patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

Hetty Carraway, MD, discusses important considerations for the future of acute myeloid leukemia regarding mutations and next-generation sequencing.

Steven Maron, MD, MSc, discusses HER2-positive tumors in esophageal gastric cancers.

Gustavo Rivero, MD, discusses evolving therapies for patients with acute myeloid leukemia with monocytic differentiation.

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Helen Heng-Shan Moon, MD, discusses the role of PARP inhibitors in prostate cancer.